115
6.
Tremolada G, Del Turco C, Lattanzio R,Maestroni S, Maestroni A, Ban-
dello F et al. The Role of Angiogenesis in the Development of Prolife-
rative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF, Treatment
Exp Diabetes Research 2012, Vol 2012 Article ID 728325, 8 pages
(
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332167/pdf/EDR2012-
728325.
pdf)
7.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of
intravitreal bevacizumab (Avastin). Ophthalmology 2007;114(5):855-9.
8.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al.
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE
study): a 12-month, randomized, controlled, double-masked, multicenter
phase II study, Diabetes Care 2010;33(11):2399–2405.
9.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al.
Ranibizumab for diabetic macular edema: results from 2 phase III rando-
mized trials: RISE and RIDE, Ophthalmology 2012;119(4):789-801.
10.
http://bmctoday.net/retinatoday/2011/01/article.asp?f=ranibizumab
-
-
approved-in-eu-for-vision-loss-due-to-diabetic-macular-edema
11.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements
/
ucm315130.htm
12.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlinge-
mann RO, et al. The RESTORE study: ranibizumab monotherapy or com-
bined with laser versus laser monotherapy for diabetic macular edema,
Ophthalmology 2011;118(4):615–25.
13.
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM,
et al. Diabetic Retinopathy Clínical Research Network, Expanded 2-year
follow-up of ranibizumab plus prompt or deferred laser or triamcino-
lone plus prompt laser for diabetic macular edema, Ophthalmology
2011;118(4):609-14.
14.
Ho AC, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS, Recchia FM.
Anti-Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic
Macular Edema: A Report by the American Academy of Ophthalmology.
Ophthalmology 2012 Aug 20. [Epub ahead of print]
15.
Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R,
Quhill F et al. A prospective randomized trial of intravitreal bevacizumab
or laser therapy in the management ofdiabetic macular edema (BOLT stu-
dy) 12-month data: report 2, Ophthalmology 2010;117(6):1078-86.
16.
Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R et
al. DA VINCI Study Group. One-Year Outcomes of the DA VINCI Stu-
dy of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. Ophthalmol
2012;119(8):1658-65.
17.
Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A,
Faghihi H, “Bevacizumab-augmented retinal laser photocoagulation in
proliferative diabetic retinopathy: A randomized double-masked clínical
trial, Eur J Ophthalmol, 2008;18(2):263–9.
18.
Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R, Panretinal
photocoagulation versus PRP plus intravitreal bevacizumab for high-risk